CAS: 1339928-25-4; N-Hydroxy-2-(((2-(6-Methoxypyridin-3-yl)-4-Morpholinothieno[3,2-D]Pyrimidin-6-yl)Methyl)(Methyl)Amino)Pyrimidine-5-Carboxamide

上下游产品

2-methoxy-pyridine-5-boronic acid ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate ethyl 2-oxo-1,2-dihydropyrimidine-5-carboxylate ethyl 2-chloropyrimidine-5-carboxylate

2-氧代-1,2,3,4-四氢嘧啶-5-羧酸乙酯置于bis-Triphenylphosphine-Palladium(II) Chloride,盐酸羟胺,溴,碳酸氢钠,溶剂黄146,N,N-二甲基苯胺,N,N-二异丙基乙胺,三氯氧磷体系中,用 甲醇,乙醇,二氯甲烷,N,N-二甲基苯胺,甲苯,乙腈 用作溶剂,化学反应 22.5H,反应生成N-羟基-2-[[[2-(6-甲氧基吡啶-3-基)-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基](甲基)氨基]嘧啶-5-甲酰胺
参考文献: Combination Therapy With A Phosphoinositide 3-Kinase Inhibitor With A Zinc Binding Moiety[fr] Polythérapie Avec Un Inhibiteur De Phosphoinositide 3-Kinase Avec Une Fraction De Liaison Au Zinc
标题: Combination Therapy With A Phosphoinositide 3-Kinase Inhibitor With A Zinc Binding Moiety[fr] Polythérapie Avec Un Inhibiteur De Phosphoinositide 3-Kinase Avec Une Fraction De Liaison Au Zinc
摘要:该发明提供了一种治疗癌症的方法,包括向需要的受试者施用:(A) 公式i的化合物或其药学上可接受的盐,其中r为氢或酰基;和(B) Bcl-2抑制剂;其中公式i的化合物或其药学上可接受的盐和bcl-2抑制剂以联合治疗有效的剂量进行施用.该发明还提供了一种包括公式i的化合物或其药学上可接受的盐,Bcl-2抑制剂和药学上可接受的载体或赋形剂的药物组合物.

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-12441733-B2
优先权日:2018-03-26
标题:Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
发明人：ARISTA LUCA; HEBACH CHRISTINA; HOLLINGWORTH GREGORY JOHN; HOLZER PHILIPP; IMBACH-WEESE PATRICIA; LORBER JULIEN; MACHAUER RAINER; SCHMIEDEBERG NIKO; VULPETTI ANNA; ZOLLER THOMAS
权利人:NOVARTIS AG
摘要:The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI)or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:US-11299491-B2
优先权日:2018-11-16
标 题:Synthesis of key intermediate of KRAS G12C inhibitor compound